Additionally, in humans, androgen deprivation therapy of prostate cancer has been shown to reduce the levels of VEGF-C and its receptor VEGFR-3 [112], but the individual net effect and the vascular response might be different for early versus late stages of the disease [113], and increased VEGF-C levels appear to dominate during the rebound and disease progression phase both in clinical studies as well as in cell culture experiments [114,115,116,117]. The gene discussed is VEGFC; the disease is Familial prostate cancer.